CN102448468B - Pharmaceutical composition for prevention or treatment of lifestyle-related disease, and food useful for prevention or treatment of lifestyle-related disease - Google Patents
Pharmaceutical composition for prevention or treatment of lifestyle-related disease, and food useful for prevention or treatment of lifestyle-related disease Download PDFInfo
- Publication number
- CN102448468B CN102448468B CN201080023787.3A CN201080023787A CN102448468B CN 102448468 B CN102448468 B CN 102448468B CN 201080023787 A CN201080023787 A CN 201080023787A CN 102448468 B CN102448468 B CN 102448468B
- Authority
- CN
- China
- Prior art keywords
- sugar
- polymerization
- degree
- component
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 37
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 37
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 18
- 230000002265 prevention Effects 0.000 title claims abstract description 16
- 235000013305 food Nutrition 0.000 title claims abstract description 15
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 36
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims abstract description 28
- 235000013353 coffee beverage Nutrition 0.000 claims description 24
- 150000002632 lipids Chemical class 0.000 claims description 24
- 150000001720 carbohydrates Chemical class 0.000 claims description 20
- 235000016213 coffee Nutrition 0.000 claims description 20
- 210000004185 liver Anatomy 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 15
- 229920000057 Mannan Polymers 0.000 claims description 13
- 238000010521 absorption reaction Methods 0.000 claims description 11
- 230000007062 hydrolysis Effects 0.000 claims description 6
- 238000006460 hydrolysis reaction Methods 0.000 claims description 6
- 241000533293 Sesbania emerus Species 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 17
- 238000004508 fractional distillation Methods 0.000 description 13
- 239000000843 powder Substances 0.000 description 12
- 230000037396 body weight Effects 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 239000000178 monomer Substances 0.000 description 8
- 241000186016 Bifidobacterium bifidum Species 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 235000020824 obesity Nutrition 0.000 description 7
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 239000003456 ion exchange resin Substances 0.000 description 6
- 229920003303 ion-exchange polymer Polymers 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- 244000182067 Fraxinus ornus Species 0.000 description 4
- 235000002917 Fraxinus ornus Nutrition 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000003463 adsorbent Substances 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000009423 ventilation Methods 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241000228245 Aspergillus niger Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 240000005384 Rhizopus oryzae Species 0.000 description 2
- 235000013752 Rhizopus oryzae Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 238000005903 acid hydrolysis reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 235000021539 instant coffee Nutrition 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000003014 ion exchange membrane Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- WNUUWQUNTSGWGN-UHFFFAOYSA-N 2-(cyclohexylcarbamoyloxy)ethyl 3-acetamido-2,4,6-triiodobenzoate Chemical compound CC(=O)NC1=C(I)C=C(I)C(C(=O)OCCOC(=O)NC2CCCCC2)=C1I WNUUWQUNTSGWGN-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 108010059892 Cellulase Proteins 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000000857 Hepatic Insufficiency Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000209051 Saccharum Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- LHAOFBCHXGZGOR-NAVBLJQLSA-N alpha-D-Manp-(1->3)-alpha-D-Manp-(1->2)-alpha-D-Manp Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1 LHAOFBCHXGZGOR-NAVBLJQLSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229940106157 cellulase Drugs 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000909 electrodialysis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229940059442 hemicellulase Drugs 0.000 description 1
- 108010002430 hemicellulase Proteins 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 150000002699 mannoheptose derivatives Chemical class 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 150000002972 pentoses Chemical class 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000012610 weak anion exchange resin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F5/00—Coffee; Coffee substitutes; Preparations thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract
- A23V2200/3202—Prebiotics, ingredients fermented in the gastrointestinal tract by beneficial microflora
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Disclosed is a pharmaceutical composition for preventing or treating lifestyle-related disease. Also disclosed is a food useful for the prevention or treatment of lifestyle-related disease. The pharmaceutical composition contains, as an active ingredient, a sugar in which a mannose unit makes up 66% or more in terms of the number of mannose units and which has a polymerization degree of 3 to 10.
Description
Technical field
The mannooligo saccharide that the present invention relates to comprise the specific degree of polymerization, for preventing or treat pharmaceutical composition and the food of diseases due to habit disturbance.
Background technology
Obesity is to be caused by the picked-up of the caused higher fatty acid property food of Occidentalizing of diet, daily exercise deficiency and excessive the caused reasons such as surfeit of pressure, is the trend increasing year by year.In addition, obesity causes accumulating in liver the diseases due to habit disturbances such as a lot of lipids, induced Diabetic, hypertension, hyperlipemia and heart disease or apoplexy.Therefore,, aspect preventing life style-related diseases, prevention of obesity becomes very important key element.Particularly be about to welcome in the modern times of aging society, the increase of diseases due to habit disturbance has become problem, from the angle of preventive medicine, also in concern, prevents fat method.Therefore, people explore and prevent fat material or its effect is studied from various food, and wherein mannooligo saccharide receives publicity.
In TOHKEMY 2006-169256, disclose mannooligo saccharide and there is the effect that improves serum lipids, TOHKEMY 2008-022778 discloses the effect that mannooligo saccharide has prevent diabetes, and TOHKEMY 2006-083127 discloses mannooligo saccharide and has the effect that reduces the diseases due to habit disturbance that the preventions such as effect of body fat cause by obesity.In addition, japanese food engineering Hui Chi .6 (4), 301-304 (2005) has reported that mannooligo saccharide has the effect of the fatty absorption that inhibition absorbs, medical science と pharmacy .54 (4), and 505-509 (2005) has reported that mannooligo saccharide has the effect that reduces liver lipid.
But people also do not know up to now: due to the difference of the degree of polymerization of mannooligo saccharide, large change occurs the degree of its effect.
Prior art document
Patent documentation
Patent documentation 1: TOHKEMY 2006-169256
Patent documentation 2: TOHKEMY 2008-022778
Patent documentation 3: TOHKEMY 2006-083127
Non-patent literature
Non-patent literature 1: japanese food engineering Hui Chi .6 (4), 301-304 (2005)
Non-patent literature 2: medical science と pharmacy .54 (4), 505-509 (2005)
Summary of the invention
Invent problem to be solved
The object of the invention is to: the pharmaceutical composition that is provided for prevention or treatment diseases due to habit disturbance.The present invention also aims to: provide the food that helps preventing life style-related diseases.
Solve the method for problem
The inventor etc. in order to achieve the above object, the sugar that has strictly screened the mannooligo saccharide of having reported forms, the monomer that discovery forms with 3～10 the degree of polymerization or their mixture suppress fat or saccharic is taken in body, reduce the lipid of accumulating in liver more potently.The inventor etc. also find: such mixture promotes the propagation of bacillus bifidus (bifidobacteria).
The present invention relates to for preventing or treat the pharmaceutical composition of diseases due to habit disturbance, this pharmaceutical composition is usingd number as benchmark accounts for more than 66%, the degree of polymerization is 3～10 sugar is as effective ingredient with mannose unit.Preferably effective ingredient is that number be take as benchmark accounts for more than 90%, more preferably accounts for the sugar that more than 95% degree of polymerization is 3～10 in mannose unit, the sugar that most preferably to be the degree of polymerization that is only comprised of mannose unit be 3～10.
In preferred version, sugar of the present invention obtains by hydrolysis process mannan, and this mannan is preferably obtained by coffee bean and/or coffee extract residue.
In preferred version, mannooligo saccharide of the present invention is β-Isosorbide-5-Nitrae-mannooligo saccharide.
In preferred version, the diseases due to habit disturbance of preventing or treating is absorbed and is caused by fat absorption and/or saccharic, the diseases due to habit disturbance particularly preferably causing for the increase by liver lipid.
The method that the invention still further relates to prevention or treatment diseases due to habit disturbance, the method comprises: the aforementioned pharmaceutical compositions that gives effective dose to likely suffering from or suffer from the patient of diseases due to habit disturbance.
The invention still further relates to: mannose unit take number as benchmark accounts for more than 66%, the degree of polymerization is 3～10 sugar in manufacture for preventing or treat the application of the medicine of diseases due to habit disturbance.
The invention still further relates to: comprising mannose unit, to take number be the sugared food that benchmark accounts for more than 66%, the degree of polymerization is 3～10.
Invention effect
Pharmaceutical composition of the present invention demonstrate potent lipid and/or saccharic absorption inhibitory action, reduce the fat of accumulating in liver, therefore performance reduces the effect of interior fat, the effect that improves serum lipids, inhibition blood glucose value reduces or the effect of rising, the effect that suppresses blood pressure drops or rising etc., and then effective to the prevention of the diseases due to habit disturbances such as obesity, metabolism syndrome, hyperlipemia, diabetes, myocardial infarction, arteriosclerosis, cerebral infarction, apoplexy, angina pectoris, hypercholesterolemia or treatment.Pharmaceutical composition of the present invention has the effect that promotes bacillus bifidus propagation, therefore also effective with diseases due to habit disturbances such as prevention or treatment cancers to keeping well enteral environment.The food of the present invention that can absorb by the diet of every day in addition, contributes to preventing life style-related diseases.
Accompanying drawing explanation
Fig. 1 shows the component inhibition lipid absorption obtaining by giving embodiment 1.
Fig. 2 shows the component minimizing liver lipid obtaining by giving embodiment 3.
Fig. 3 shows by giving component that embodiment 3 obtains and suppresses saccharic and absorb.
The specific embodiment
It is the sugar that benchmark accounts for more than 66%, the degree of polymerization is 3～10 that number be take in mannose unit in the present invention, also usings at least one of the such monosaccharide of glucose, fructose and galactose as Component units except mannose.
Above-mentioned sugar is to do one's utmost to remove from comprising to take the hydrolysate of mannan of the oligosaccharide that mannose that the degree of polymerization is 1～10 is main body the component that the degree of polymerization obtains as the sugar below 2.The mannan being hydrolyzed can be from any supply source.For example can enumerate: mannan contained in the plant Huacra Palm of Cortex cocois radicis section, large and Rhizoma Dioscoreae (Star Network ネ イ モ) mannan, Rhizoma Dioscoreae (ヤ モ イ モ) mannan are produced in coffee bean, coffee extract residue, the copra meal being obtained by Cortex cocois radicis or South Africa.The mannan particularly preferably being obtained by coffee bean and/or coffee extract residue.
This component conventionally take the mannooligo saccharide that mannose unit is 3～10 each monomer, be that the mixture of mannotriose, mannotetrose, manna pentose, manna six sugar, mannoheptose, manna eight sugar, manna nonoses and manna sugar in the last of the ten Heavenly stems is main component, but can be to be also further fractionated into each monomer and the component that obtains.In component of the present invention, although the degree of polymerization that can residual minim is the oligosaccharide below 2, but preferred minute quantity, preferably to take number be the sugar that benchmark accounts for more than 90%, the degree of polymerization is 3～10 in mannose unit, more preferably contain more than 95% the sugar that the degree of polymerization being most preferably only comprised of mannose unit is 3～10.
Take number and occupy more than 66% as benchmark in mannose unit in the present invention, the degree of polymerization is that 3～10 sugar preferably can obtain as follows: utilize and be selected from acid hydrolysis, high-temperature heating hydrolysis, enzyme hydrolysis, one kind or two or more method in microorganism fermentation is processed the raw bean of coffee, contained mannan in the coffee bean that roasting is decocted or used coffee residue, pass through again charcoal treatment, adsorbent resin is processed, ion exchange resin treatment, the method purification such as ion exchange membrane processing, separated with coffee residue afterwards, by ion-exchange chromatography or ethanol equal solvent, process that to do one's utmost to remove the degree of polymerization be that component below 2 obtains.
The acid of using in acid hydrolysis can be sulphuric acid, hydrochloric acid.Acid degree is pH0～2.The temperature of high-temperature heating hydrolysis is 190～250 ℃.Enzyme hydrolysis, by the supply source of mannan or mannan is suspended in aqueous medium, adds afterwards such as commercially available cellulase and hemicellulase etc. and stirs and carry out.The concentration of the oxygen using is 0.01%～1%, and temperature is 30～80 ℃.The bacterial strain using in microorganism fermentation can be aspergillus niger (Aspergillus niger), bacillus subtilis (Bacillus subtilis), Rhizopus oryzae (Rhizopus oryzae).
The resin that adsorbent resin is used in processing can be enumerated SDVB polymer.The ion exchange resin using in ion exchange resin treatment can be enumerated SK-1B.
As being the filler using in the ion-exchange chromatography that carries out of the component below 2 in order to do one's utmost to remove the degree of polymerization, can enumerate UBK-530, UBK-510L.Fill respectively two kinds of ion exchange resin, afterwards by the post several of series connection, thereby can obtain more highly purified component.
The reactant liquor that contains the component obtaining by said method as required can purification.Purification process has: the decoloration and deodorization being undertaken by bone black, active carbon, carbonation method, adsorbent resin, magnesium oxide method, solvent extraction etc.; Desalination or the deacidification by ion exchange resin, ion exchange membrane, electrodialysis etc., undertaken.Purification condition can suitably be selected according to amount and other essential factors of the pigment in reactant liquor, salt and acid etc.These purification process can combine.
The discoveries such as the inventor: the degree of polymerization being only comprised of mannose unit is more than 3, preferred degree of polymerization is more than 4 monomer potent performance fat absorption inhibition and saccharic absorption inhibition.The inventor etc. also find: mannose unit take number as benchmark accounts for the sugared component that more than 90% degree of polymerization is 3～10, significantly reduce liver lipid.Known by these results: suppressing the absorption of fat and sugar matter, efficiently reducing aspect the lipid in liver, take number and account for more than 66%, preferably more than 90%, more preferably more than 95%, most preferably sugared mixture or a monomer that the degree of polymerization being comprised of mannose unit is 3～10 are effective as benchmark in mannose unit.
The prevention of the diseases due to habit disturbance in the present invention or treatment, can suppress lipid absorption and saccharic absorbs by orally ingestible pharmaceutical composition of the present invention.Owing to can independently suppressing the systemic lipid amount of body or saccharic amount with the fat of diet or the amount of saccharic of picked-up, thus the hobby of diet can not be changed, can the caused diseases due to habit disturbance of prevention of obesity.
Liver lipid minimizing in the present invention refers to, by suppressing the systemic lipid amount of body and/or saccharic amount, reduces neutral fat and the T-CHOL in liver, accumulated.As long as can reduce liver fat, not only can reach the direct preventive effect of hyperlipemia or hypercholesterolemia, the diseases due to habit disturbances such as all right wide scope ground prevent diabetes, arteriosclerosis, hepatic insufficiency.
The discoveries such as the inventor: the degree of polymerization being only comprised of mannose unit is the propagation that more than 4 monomers also promotes bacillus bifidus.From this result: in the propagation that promotes bacillus bifidus, well to keep aspect the diseases due to habit disturbances such as enteral environment, prevention colorectal cancer, take number and account for more than 66%, preferably more than 90%, more preferably more than 95%, most preferably sugared mixture or monomer that the degree of polymerization being comprised of mannose unit is 3～10 are also effective as benchmark in mannose unit.
Of the present inventionly for the pharmaceutical composition preventing or treat diseases due to habit disturbance, can make the preparation of form arbitrarily such as tablet, powder, granule, capsule, dragee, syrup together with excipient and other additives.As excipient and additive, can enumerate: the solid matters such as lactose, sucrose, crystalline cellulose, corn starch, agar, pectin, stearic acid, magnesium stearate, lecithin, sodium chloride; The liquids such as glycerol, polyvinylpyrrolidone, olive oil, ethanol, benzyl alcohol, propylene glycol, water.In pharmaceutical composition, mannose unit take number and accounts for 0.1～100% (weight) that the amount of the sugared component that more than 66% degree of polymerization is 3～10 is pharmaceutical composition total amount, preferably 1～100% (weight), 5～95% (weight) more preferably as benchmark.
While giving pharmaceutical composition of the present invention to human oral, the amount of component of the present invention depends on age, body weight, sex, medication etc. and changes, and the male's intake for each person every day of being for example grown up is approximately 10～500mg/kg body weight, about 30～70mg/kg body weight more preferably preferably.
Take number and account for sugared food that more than 66% degree of polymerization is 3～10 such as having as benchmark in the mannose unit that comprises in the present invention: liquid coffee, instant coffee and coffee bland etc.Liquid coffee has: commercially available in tank filling or so-called PET bottle container, be known as coffee beverage or containing the coffee of the beverage of coffee; Instant coffee has: by decocting with hot water extraction roasting the extracting solution of pulverizing coffee and obtaining, by spraying or freeze-drying method, remove that moisture obtains, to be known as soluble powder coffee coffee.Coffee bland has: in soluble powder coffee, add, mix Saccharum Sinensis Roxb., cream powder (creaming powder) etc. and the beverage that obtains etc.In these food, mannose unit take number and accounts for 0.1～80% (weight) that sugared ratio that more than 66% degree of polymerization is 3～10 is food total amount, preferably 1～70% (weight), 3～60% (weight) more preferably as benchmark.
Embodiment
The present embodiment is used for illustrating embodiments of the present invention, not delimit the scope of the invention.
embodiment 1
the high-purity fractional distillation of mannooligo saccharide
Utilize the filtration system of commercial use, the roasting that extraction 10kg obtains by conventional method is decocted and is pulverized coffee concentrated, obtains 7kg coffee extract residue (dry weight).
This residue is crushed to the about 1mm of particle diameter, sends into afterwards in the hot plug flow reactor of 4m.Then add water, make the serosity that total solid constituent concentration is approximately 14% (weight), heat-treat afterwards.With corresponding speed of 8 minutes holdup times, itself and high steam are together pumped in plug flow reactor, use 6.35mm φ orifice plate to maintain approximately 210 ℃.Afterwards, under atmospheric pressure spray with emergent stopping and react.In the coffee extract solution that comprises mannooligo saccharide at 1kg, add 200g active carbon, be heated to 60 ℃, then stir 1 hour, add afterwards kieselguhr, after stirring, filter.Filtrate is successively by being filled with the post and the post that is filled with weak anion exchange resin (Daiaion SA-12A) of strong cation-exchanging resin (Daiaion SK-1B), vacuum lyophilization afterwards, obtains the solid constituent that 650g only comprises mannose and mannooligo saccharide.
By being in series with the column chromatography of two kinds of ion exchange resin (Daiaion UBK-510L and UBK-530) on the post at internal diameter 40 φ, long 1500mm, obtain the high-purity component of the various degree of polymerization (Degree of Polymerization, hereinafter referred to as " DP ").
In this operation, keep post and mobile phase at 65 ℃.Flow velocity is 20ml/ minute, the sample of the sample of supply column chromatography for adding 20g water dissolution to obtain in the above-mentioned solid constituent of 10g.After the component that the mannooligo saccharide that obtains take specific DP is main component, repeat to be re-injected the operation in post, obtain containing separately respectively the high-purity component of more than 90% DP2, DP3, DP4 and DP5.About component more than DP6, obtained DP6～10 and added up to more than 90% component.Here, for example DP3 refers to the mannooligo saccharide of the mannose unit that only comprises 3.By the vacuum lyophilization respectively of each component.Composition in the dry thing of each component is in Table 1.
[table 1]
embodiment 2
by giving the component that embodiment 1 obtains, suppress lipid absorption
In experiment, using SD is male Wistar rat.Carry out the raising of giving of 7 days, double as between quarantine and domestication, the individuality of body weight change and general state no abnormality seen is divided into 6 groups, 10 every group, supply with experiment.Letting animals feed under the environment of having controlled temperature, humidity, rate of ventilation and lighting hours.In 6mL Semen Maydis oil, add 80mg cholic acid, 2g cholesterol acid ester, the ratio with 6mL water for injection adds afterwards, and ultrasonic Treatment 10 minutes, with the liquid in contrast of the liquid in suspended state.In this contrast liquid, add DP2, DP3, DP4, DP5 and each more than DP6 component that fractional distillation product, embodiment 1 do not obtain, make to reach 700mg/2mL contrast liquid/kg body weight, thus preparation experiment sample.Use injection tube and feeding pin (feeding needle), to the animal under not anaesthetizing, force per os to give each experimental sample.Before administration, after administration 30,60,120,180,240 and 330 minutes under anesthesia not from tail vein blood, use commercially available triglyceride determination test kit, measure the neutral fat content in serum, calculate this time memory total fat mass.
It the results are shown in Table 2 and Fig. 1.
[table 2]
With regard to neutral fat amount in blood, compare with matched group, fractional distillation product and component administration group do not demonstrate the trend of step-down.Compare with DP2 group with fractional distillation product group not, each more than DP3 group demonstrates the trend of step-down.Known by this result: although give not fractional distillation product or each component also can reduce neutral fat amount in blood, by the form with mixture or monomer, to give component more than DP3, bring into play the effect of more excellent inhibition fat absorption.
embodiment 3
the preparation of high DP component, middle DP component, low DP component
In the solid constituent that only comprises mannose and mannooligo saccharide obtaining to 10g embodiment 1, add 20g water dissolution, utilize the method identical with embodiment 1 to carry out fractional distillation.Wherein, use fraction collector that eluent is fractionated into each 50ml, the component that eluting capacity reaches 1200～1450ml is high DP component, and the component that eluting capacity reaches 1450～1650ml is middle DP component, and the component that eluting capacity reaches 1650～2100ml is low DP component.By the vacuum lyophilization respectively of each component, for test.Content in dry thing is in Table 3.
[table 3]
embodiment 4
by giving the component that embodiment 3 obtains, reduce liver lipid
In experiment, using ICR is female mice.Carry out the raising of giving of 7 days, double as between quarantine and domestication, the individuality of body weight change and general state no abnormality seen is divided into 5 groups, 8 every group, supply with experiment.Letting animals feed under the environment of having controlled temperature, humidity, rate of ventilation and lighting hours.About experiment feedstuff, the high fat diet that allowed animal freely absorb to contain 40% Adeps Bovis seu Bubali in 56 days is the feedstuff of basis each component that is mixed with 1% not fractional distillation product, low DP, middle DP and high DP and does not add the feedstuff (control feed) of component.After giving to finish during feedstuff, take liver, in the liver organization of about 0.5g, add the cold 0.1M PBS of 4.5mL, homogenate, centrifugal with the rotating speed of 3000rpm afterwards, gather supernatant.Take supernatant as sample, use commercially available triglyceride determination kit measurement lipid amount.
It the results are shown in Table 4 and Fig. 2.
[table 4]
Compare with matched group, in the liver of fractional distillation product and each component administration group, lipid does not obviously tail off.Compare with low DP component group with fractional distillation product group not, in the liver of middle DP component group and high DP component group, lipid obviously tails off.From this result: by giving each component, in liver, lipid tails off, but middle DP component wherein and the administration of high DP component further reduce lipid in liver.This hint: by contain for a long time more than 90% middle DP component above, be mixture more than DP3, performance reduces the effect of liver lipid more significantly.
embodiment 5
by giving high DP component that embodiment 3 obtains, suppress saccharic and absorb
Using Wister is male rat.Carry out the raising of giving of 7 days, double as between quarantine and domestication, afterwards the individuality of body weight increase and general state no abnormality seen is divided into 3 groups, 10 every group, supply with experiment.Letting animals feed under the environment of having controlled temperature, humidity, rate of ventilation and lighting hours.Matched group is used the starch of water dissolution 12g/kg body weight and the sample that obtains, not fractional distillation the group starch of water dissolution 12g/kg body weight and the mannooligo saccharide of 1.7g/kg body weight not fractional distillation product and the sample that obtains, and high DP group is used the high DP that the starch of water dissolution 12g/kg body weight and the embodiment 3 of 1.7g/kg body weight obtain and the sample obtaining.Use injection tube and feeding pin, under anesthesia, do not forcing oral administration.Before administration, after administration 15 minutes, 30 minutes, 60 minutes, 120 minutes, 180 minutes and 240 minutes under anesthesia not from the tail vein blood of each animal.Use commercially available kit measurement blood glucose value, the interior total blood glucose amount existing between calculating at this moment.
It the results are shown in Table 5 and Fig. 3.
[table 5]
Compare with not fractional distillation group with matched group, total blood glucose amount of high DP group demonstrates the trend of step-down.This result shows: by giving as the mixture more than DP3 of high DP, saccharic absorbs and is inhibited.
embodiment 6
the impact of the component that embodiment 3 obtains on intestinal flora
For control feed group and the high DP component group of embodiment 4, after finishing, gather the cecal content of full dose during its administration, carry out immediately ice-coldly, measure flora.This mensuration according to the method on light ridge (the “Intestinal Nei bacterium world " light ridge volume content with one's lot, 1984 distribution, Winter Solstice study Xin She) carry out.Using total anaerobe number (the colony number in EG culture medium or BL culture medium) and TABC (the colony number in TS culture medium) sum as total bacteria count.Wherein, according to the form of the shape of the colony in BL culture medium, Gram's staining and cell, determine Bifidobacteria population counting, as bacillus bifidus number, calculate bacillus bifidus shared ratio in total bacteria count.The results are shown in Table 6.The ratio that confirms bacillus bifidus in high DP component group increases.
[table 6]
| Control feed group | High DP component group |
| 10.7％ | 20.3％ |
embodiment 7
the preparation method of tablet
In the 50% more than DP6 obtaining to embodiment 1 component powders, mix 20% lactose, 20% starch, 6% crystalline cellulose, add afterwards 10% alcoholic solution of hydroxypropyl cellulose to make to reach 3%, carry out mixing granulation, the sieve that is 0.8mm by diameter is extruded, prepare granule dry, with 1% amount, add magnesium stearate afterwards, by compression molded, prepare the tablet that 1 is 300mg.By taking this tablet of 3 left and right every day, can expect preventive effect or the therapeutic effect of diseases due to habit disturbance.
embodiment 8
the preparation method of powder agent
In the 90% more than DP6 obtaining to embodiment 1 fractional distillation powder, add 10% dextrin and water, use that fluidized bed pelletizer mixes, heating, pelletize, obtain granules.Use excellent filling machine (stick filler) by the granules of gained directly or its powder pulverized powder be filled in rod (stick), make every rod reach 2g.By taking this powder agent of 1 bag left and right every day, can expect preventive effect or the therapeutic effect of diseases due to habit disturbance.
embodiment 9
the preparation of coffee beverage
In 3g the component powders more than DP6 obtaining to embodiment 1, concentrated coffee extracting solution (11g coffee solid composition) and 0.17g artificial sweetening agent, add 1000ml water to dilute, after UHT sterilization, be filled in PET bottle.The more original coffee beverage of this coffee beverage has denseer caf, can continue picked-up every day, can expect to contribute to preventing life style-related diseases.
Industrial applicability
The compositions with diseases due to habit disturbance prevention or curative function of the present invention, not only can be at medicine field, can also in field, use widely at cosmetics, diet product, feedstuff etc., can expect the effect of the diseases due to habit disturbance that prevention or treatment are caused by obesity.
Claims (11)
1. pharmaceutical composition, it is for prevention or treatment diseases due to habit disturbance, and this pharmaceutical composition comprises mannose unit and using number as benchmark accounts for more than 66%, the degree of polymerization is 3～10 sugar is as effective ingredient, and wherein the degree of polymerization is that sugar below 2 is removed.
2. compositions claimed in claim 1, wherein, above-mentioned sugar is that to take number be the sugar that benchmark accounts for more than 90%, the degree of polymerization is 3～10 in mannose unit.
3. compositions claimed in claim 1, wherein, the sugar that above-mentioned sugar is 3～10 for the degree of polymerization that is only comprised of mannose unit.
4. compositions claimed in claim 3, wherein, above-mentioned sugar is β-Isosorbide-5-Nitrae-mannooligo saccharide.
5. compositions claimed in claim 1, wherein, above-mentioned sugar obtains by hydrolysis process mannan.
6. compositions claimed in claim 5, wherein, above-mentioned mannan is obtained by coffee bean and/or coffee extract residue.
7. compositions claimed in claim 1, wherein, above-mentioned diseases due to habit disturbance is caused by fat absorption.
8. compositions claimed in claim 1, wherein, above-mentioned diseases due to habit disturbance is absorbed and is caused by saccharic.
9. the compositions described in claim 7 or 8, wherein, above-mentioned diseases due to habit disturbance is that the increase by liver lipid causes.
Mannose unit take number as benchmark accounts for more than 66%, the degree of polymerization is 3～10 sugar in manufacture for preventing or treat the application of the medicine of diseases due to habit disturbance.
11. food, wherein comprising mannose unit, to take number be the sugar that benchmark accounts for more than 66%, the degree of polymerization is 3～10, and wherein the degree of polymerization is that sugar below 2 is removed.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2009/056115 WO2010109626A1 (en) | 2009-03-26 | 2009-03-26 | Pharmaceutical composition for prevention or treatment of lifestyle-related diseases and food useful therefor |
| JPPCT/JP2009/056115 | 2009-03-26 | ||
| PCT/JP2010/055078 WO2010110313A1 (en) | 2009-03-26 | 2010-03-24 | Pharmaceutical composition for prevention or treatment of lifestyle-related disease, and food useful for prevention or treatment of lifestyle-related disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102448468A CN102448468A (en) | 2012-05-09 |
| CN102448468B true CN102448468B (en) | 2014-12-03 |
Family
ID=42780335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201080023787.3A Expired - Fee Related CN102448468B (en) | 2009-03-26 | 2010-03-24 | Pharmaceutical composition for prevention or treatment of lifestyle-related disease, and food useful for prevention or treatment of lifestyle-related disease |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9101648B2 (en) |
| EP (1) | EP2412375A4 (en) |
| KR (1) | KR101723529B1 (en) |
| CN (1) | CN102448468B (en) |
| BR (1) | BRPI1009843A2 (en) |
| WO (2) | WO2010109626A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220378060A1 (en) * | 2020-02-19 | 2022-12-01 | Robert Christoper RUETER | System and method for accelerating extraction of ingredients into a product |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101087621A (en) * | 2004-09-17 | 2007-12-12 | 味之素通用食品株式会社 | Compositions having body fat reducing function and food and drink containing the same |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH635485A5 (en) | 1978-08-22 | 1983-04-15 | Coffex Ag | METHOD FOR DECOFFINATING RAW COFFEE. |
| JPS62111671A (en) | 1985-11-11 | 1987-05-22 | Ajinomoto General Foods Kk | Production of natural antioxidant for food from raw coffee bean |
| CA1324287C (en) | 1988-09-14 | 1993-11-16 | Howard Dave Stahl | Process for hydrolyzing a partially extracted roasted and ground coffee |
| JP3477628B2 (en) | 1995-06-19 | 2003-12-10 | アサヒビール株式会社 | Polyphenol preparation obtained from hop bract and its manufacturing method |
| JPH09143465A (en) | 1995-11-21 | 1997-06-03 | Dainippon Ink & Chem Inc | Antioxidative composition |
| JP3855293B2 (en) | 1996-02-14 | 2006-12-06 | 長谷川香料株式会社 | Antioxidant composition |
| US6576275B1 (en) | 1999-02-02 | 2003-06-10 | Archer-Daniels-Midland Company | Process for extracting polyphenolic antioxidants from purine-containing plants |
| DE19961182B4 (en) | 1999-12-18 | 2006-01-12 | Südzucker AG Mannheim/Ochsenfurt | Galactomannan oligosaccharides and process for their preparation and their use |
| JP4179741B2 (en) | 2000-09-22 | 2008-11-12 | アサヒ飲料株式会社 | Beverages containing apple polyphenols |
| JP2002262827A (en) * | 2001-03-13 | 2002-09-17 | Ajinomoto General Foods Inc | Serum lipid improving composition containing mannooligosaccharide |
| JP3691453B2 (en) | 2002-04-30 | 2005-09-07 | アサヒ飲料株式会社 | Coffee beverage and method for producing the same |
| JP2004267177A (en) | 2003-03-04 | 2004-09-30 | Servicetec Japan Corp | Method for removing polyphenol in liquid |
| JP4113829B2 (en) | 2003-10-24 | 2008-07-09 | 株式会社 伊藤園 | Glutamic acid-containing food material and method for producing the same |
| US8252769B2 (en) | 2004-06-22 | 2012-08-28 | N. V. Nutricia | Intestinal barrier integrity |
| JP2006042624A (en) | 2004-08-02 | 2006-02-16 | Ajinomoto General Foods Inc | Chlorogenic acid-containing beverage |
| JP4960591B2 (en) * | 2004-12-14 | 2012-06-27 | 味の素ゼネラルフーヅ株式会社 | Anti-allergen composition containing mannooligosaccharides |
| WO2006064761A1 (en) | 2004-12-17 | 2006-06-22 | Asahi Breweries, Ltd. | Adiponectin regultor and foods, drinks, food aditives and drugs containing the same |
| JP2006193502A (en) | 2004-12-17 | 2006-07-27 | Asahi Breweries Ltd | Adiponectin regulating agent and food, drink, food additive and medicine containing the same |
| JP4705628B2 (en) | 2005-02-03 | 2011-06-22 | 太陽化学株式会社 | Composition for prevention, amelioration or treatment of diabetes and / or diabetic nephropathy |
| JP4955928B2 (en) | 2005-03-01 | 2012-06-20 | 花王株式会社 | Method for producing chlorogenic acid composition |
| JP2006306799A (en) | 2005-04-28 | 2006-11-09 | Kao Corp | Method of producing chlorogenic acids composition |
| US20060286238A1 (en) | 2005-06-20 | 2006-12-21 | The Procter & Gamble Company | Processes for isolating bitter quinides for use in food and beverage products |
| JP4673753B2 (en) | 2006-01-16 | 2011-04-20 | 味の素ゼネラルフーヅ株式会社 | Serum lipid improving agent containing mannooligosaccharide |
| KR101300336B1 (en) * | 2006-01-24 | 2013-08-28 | 아지노모또 제네럴 푸즈, 인크. | Composition having effect of lowering blood pressure and/or inhibiting increase in blood pressure and food and drink containing the same |
| JP5021223B2 (en) | 2006-03-16 | 2012-09-05 | ユニチカ株式会社 | Adiponectin secretion promoter, insulin resistance improving agent and anti-atherosclerotic agent |
| JP4851215B2 (en) * | 2006-03-27 | 2012-01-11 | 味の素ゼネラルフーヅ株式会社 | Mineral absorption promoting composition containing mannooligosaccharide |
| JP4771882B2 (en) | 2006-07-21 | 2011-09-14 | 味の素ゼネラルフーヅ株式会社 | Composition having action of treating, preventing or ameliorating diabetes or diabetic complication and beverage containing the same |
| EP2196208A4 (en) | 2007-09-26 | 2010-09-22 | Takasago Perfumery Co Ltd | Plant extract and use thereof |
| JP5054499B2 (en) | 2007-12-10 | 2012-10-24 | 花王株式会社 | Lipid metabolism improver |
| JP4667514B2 (en) | 2009-05-07 | 2011-04-13 | 味の素ゼネラルフーヅ株式会社 | Chlorogenic acid-containing beverage |
-
2009
- 2009-03-26 WO PCT/JP2009/056115 patent/WO2010109626A1/en active Application Filing
-
2010
- 2010-03-24 CN CN201080023787.3A patent/CN102448468B/en not_active Expired - Fee Related
- 2010-03-24 BR BRPI1009843A patent/BRPI1009843A2/en not_active IP Right Cessation
- 2010-03-24 EP EP10756109A patent/EP2412375A4/en not_active Withdrawn
- 2010-03-24 WO PCT/JP2010/055078 patent/WO2010110313A1/en active Application Filing
- 2010-03-24 US US13/260,405 patent/US9101648B2/en active Active
- 2010-03-24 KR KR1020117025166A patent/KR101723529B1/en active IP Right Grant
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101087621A (en) * | 2004-09-17 | 2007-12-12 | 味之素通用食品株式会社 | Compositions having body fat reducing function and food and drink containing the same |
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI1009843A2 (en) | 2016-03-15 |
| CN102448468A (en) | 2012-05-09 |
| EP2412375A1 (en) | 2012-02-01 |
| WO2010110313A1 (en) | 2010-09-30 |
| KR20120008036A (en) | 2012-01-25 |
| US9101648B2 (en) | 2015-08-11 |
| US20120101058A1 (en) | 2012-04-26 |
| KR101723529B1 (en) | 2017-04-05 |
| EP2412375A4 (en) | 2012-09-26 |
| WO2010109626A1 (en) | 2010-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101822697B (en) | Preparation method of traditional Chinese medicine ultrafine formula particles | |
| JP4771882B2 (en) | Composition having action of treating, preventing or ameliorating diabetes or diabetic complication and beverage containing the same | |
| KR100970455B1 (en) | Method for preparing extract of ginseng using ultra high pressure | |
| MX2008014659A (en) | Guava leaf extract powder and method for production thereof. | |
| EP1980258A1 (en) | Composition having effect of lowering blood pressure and/or inhibiting increase in blood pressure and food and drink containing the same | |
| CN106109488A (en) | The application in preparing the food or medicine with blood fat reducing function of a kind of Quinoa polysaccharide | |
| CN102448468B (en) | Pharmaceutical composition for prevention or treatment of lifestyle-related disease, and food useful for prevention or treatment of lifestyle-related disease | |
| KR100949247B1 (en) | Method for producing processed ginseng or processed ginseng extract | |
| JP3507115B2 (en) | Banaba leaf extract and antidiabetic agent | |
| EP2412374A1 (en) | Pharmaceutical composition for enhancing adiponectin production and food useful therefor | |
| KR20100018018A (en) | Method for producing processed ginseng or processed ginseng extract | |
| CN101569645A (en) | Smallanthus sonchifolius buccal tablet and preparation method thereof | |
| CN101491668B (en) | Composition with blood-sugar reducing function and preparation method thereof | |
| CN101642568B (en) | Rhodiola root composition | |
| JP5738180B2 (en) | Pharmaceutical composition and food useful for preventing or treating lifestyle-related diseases | |
| CN111265627B (en) | Sea cucumber polysaccharide composition for regulating intestinal flora and preparation method and application thereof | |
| CN108079271A (en) | A kind of pharmaceutical composition for treating hyperlipidemia, preparation and preparation method thereof | |
| JP4524018B2 (en) | Pharmaceutical composition and health food for prevention and treatment of non-insulin dependent diabetes mellitus comprising mulberry leaf and agaricus extract mixture | |
| CN113476525A (en) | Traditional Chinese medicine glucoside composition with lipid-lowering and weight-losing effects and preparation method and application thereof | |
| CN102793799B (en) | Buccal tablets with weight reduction effect | |
| JP2005289847A (en) | Blood sugar level rising inhibitor | |
| CN106692319A (en) | Large-specification Fengliaochangweikang dropping pill and preparation method thereof | |
| CN101024045A (en) | Special nutrient for tonifying middle aged and old men | |
| CN116077449A (en) | Preparation method of digestion-aiding Mongolian medicine Dangma-5 tablets | |
| CN111870626A (en) | Pharmaceutical composition with blood fat reducing effect and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Tokyo, Japan, Japan Patentee after: Ajinomoto General Foods K. K. Patentee after: Intercontinental Great Brands LLC Address before: Tokyo, Japan, Japan Patentee before: Ajinomoto General Foods K. K. Patentee before: Kraft Foods Global Brands LLC |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170110 Address after: Tokyo, Japan, Japan Patentee after: Ajinomoto General Foods, INC Patentee after: Sara Lee/DE B.V. Address before: Tokyo, Japan, Japan Patentee before: Ajinomoto General Foods, INC Patentee before: Intercontinental Great Brands LLC |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141203 Termination date: 20180324 |